Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15580 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Tobias Kühne und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology, Clinical Nutrition & Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Insulin, Long-Acting, Cross-Over Studies, Diabetes Mellitus, Type 1, Caffeine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Pharma, Dexcom.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate whether caffeine combined with a moderate amount of glucose reduces the risk for exercise‐related hypoglycaemia compared with glucose alone or control in adult people with type 1 diabetes using ultra‐long‐acting insulin degludec. Materials and Methods Sixteen participants conducted three aerobic exercise sessions (maximum 75 min) in a randomized, double‐blind, cross‐over design. Thirty minutes before exercise, participants ingested a drink containing either 250 mg of caffeine + 10 g of glucose + aspartame (CAF), 10 g of glucose + aspartame (GLU), or aspartame alone (ASP). The primary outcome was time to hypoglycaemia.
Results
There was a significant effect of the condition on time to hypoglycaemia (χ 2 = 7.674, p = .0216). Pairwise comparisons revealed an 85.7% risk reduction of hypoglycaemia for CAF compared with ASP ( p = .044). No difference was observed between GLU and ASP ( p = .104) or between CAF and GLU ( p = .77). While CAF increased glucose levels during exercise compared with GLU and ASP (8.3 ± 1.9 mmol/L vs. 7.7 ± 2.2 mmol/L vs. 5.8 ± 1.4 mmol/L; p < .001), peak plasma glucose levels during exercise did not differ between CAF and GLU (9.3 ± 1.4 mmol/L and 9.1 ± 1.6 mmol/L, p = .80), but were higher than in ASP (6.6 ± 1.1 mmol/L; p < .001). The difference in glucose levels between CAF and GLU was largest during the last 15 min of exercise ( p = .002). Compared with GLU, CAF lowered perceived exertion ( p = .023).
Conclusions
Pre‐exercise caffeine ingestion combined with a low dose of glucose reduced exercise‐related hypoglycaemia compared with control while avoiding hyperglycaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology, Clinical Nutrition & Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Team Novo Nordisk Professional Cycling Team, Atlanta, Georgia, USA.
ORCID-Profile: David Herzig, Andreas Melmer, Christoph Stettler
Förderung
- Novo Nordisk Pharma
- Dexcom
Zitieren
APA
Kühne, T., Wallace, E., Herzig, D., Helleputte, S., Scott, S., Pickles, J., Melmer, A., & Stettler, C. (2024). Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15580
Vancouver
Kühne T, Wallace E, Herzig D, Helleputte S, Scott S, Pickles J, et al. Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15580
BibTeX
@article{Khne2024,
author = {Kühne, Tobias and Wallace, Esmè and Herzig, David and Helleputte, Simon and Scott, Sam and Pickles, Jordan and Melmer, Andreas and Stettler, Christoph},
title = {Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15580}
}
EUVIMED